ROIV
Roivant Sciences Ltd.$28.94
LiveJun 09, 2026
Market cap
$20.81B
52w range
10.71 – 32.79
P / E
—
EPS
—
Volume
2.41M
Revenue · FY
—
Explain this page
Arphra AIPlain-English read on Roivant Sciences Ltd.’s valuationBusiness description
· company · SEC profileRoivant Sciences Ltd.
Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, warm autoimmune hemolytic anemia, thyroid eye diseases, sarcoidosis, and staph aureus bacteremia. The company was founded in 2014 and is based in London, the United Kingdom.
Founded
—
IPO
Dec 08, 2020
Employees
908
HQ
London
CEO
Matthew Gline
CFO
—
Exchange
NASDAQ
Fiscal year
—
Identifiers
· company_identifiersCIK0001635088
CUSIPG76279101
ISINBMG762791017
FIGIROIV US
LEI—
Cross-listings
· companies · ISIN- ROIVPrimaryNasdaq Stock MarketgbUSD$20.89B
- ROIVWNasdaq Stock MarketUSD—
The global universe keeps only the primary listing; the other venues for this security are shown here.